Marianne Mertens

Marianne Mertens has extensive experience in the life sciences industry. Marianne is currently a Partner at Apollo Health Ventures, where they focus on accelerating breakthrough scientific discoveries in order to build life science companies around new therapeutic technologies. Marianne also serves as a Board Observer at Auron Therapeutics, Booster Therapeutics, and SNIPR Biome - A CRISPR Company, and as a Board Director at Cleara Biotech and Wellington Partners Life Sciences.

Previously, Marianne held the role of Principal at Wellington Partners Life Sciences from 2018 to 2021. In this position, they invested in early- and growth-stage life science companies and was active in the fields of therapeutics, medical technology, diagnostics, digital health, and industrial biotechnology.

Prior to that, Marianne served as a Board Director at Confo Therapeutics from 2019 to 2021, a Board Observer at UroMems from 2019 to 2021, a Board Observer at Cardior Pharmaceuticals from 2017 to 2018, and a Board Director at PreOmics GmbH from 2017 to 2018.

Marianne Mertens has a diverse education history. In 2003, they attended RWTH Aachen University and obtained a Bachelor of Science (B.Sc.) degree in Biotechnology. Marianne continued their studies at the same university and completed a Master of Science (M.Sc.) degree in Biotechnology in 2009. During their time as a student, Marianne also had a brief study abroad experience at the University of Adelaide in 2007-2008. In 2009, they briefly enrolled in a program at Scripps Research, although specific details regarding the degree or field of study are not provided. Marianne further pursued their academic career and obtained a doctoral degree in Biotechnology from RWTH Aachen University from 2010 to 2013. Their research during this time focused on Experimental Molecular Imaging. In 2016, Marianne attended WHU - Otto Beisheim School of Management for an executive education program in Value Creation in Private Equity and Venture Capital.